More importantly, some known inhibitors, such as maraviroc, cenicriviroc, and MET‐CCL5, which could prevent the binding of CCL5 and CCR5, have demonstrated anti‐inflammatory and anti‐cancer effects in several phase I and phase II clinical trials (NCT01736813; NCT00569985; NCT03274804).[53] Therefore, elucidating the molecular mechanisms that sustain CCL5 expression and determining the precise role of the CCL5/CCR5 axis in TAM activation in GC could contribute to the development of promising therapeutic strategies. Here, MET is linked to gastric cancer.